Cargando…
High-risk additional cytogenetic aberrations in a Dutch chronic phase chronic myeloid leukemia patient population
Autores principales: | Kockerols, Camille C.B., Geelen, Inge G.P., Levin, Mark-David, Janssen, Jeroen J.W.M., Beverloo, H. Berna, Dinmohamed, Avinash G., Hoogendoorn, Mels, Cornelissen, Jan J., Westerweel, Peter E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Fondazione Ferrata Storti
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10620565/ https://www.ncbi.nlm.nih.gov/pubmed/36951166 http://dx.doi.org/10.3324/haematol.2022.282447 |
Ejemplares similares
-
The use of hydroxyurea pretreatment in chronic myeloid leukemia in the current tyrosine kinase inhibitor era
por: Kockerols, Camille C.B., et al.
Publicado: (2022) -
Treatment outcome in a population-based, ‘real-world’ cohort of patients with chronic myeloid leukemia
por: Geelen, Inge G.P., et al.
Publicado: (2017) -
Digital PCR for BCR-ABL1 Quantification in CML: Current Applications in Clinical Practice
por: Kockerols, Camille C.B., et al.
Publicado: (2020) -
Treatment patterns and clinical outcomes of asciminib in a real-world multiresistant chronic myeloid leukemia patient population
por: Kockerols, Camille C.B., et al.
Publicado: (2022) -
New Approaches and Treatment Combinations for the Management of Chronic Myeloid Leukemia
por: Westerweel, Peter E., et al.
Publicado: (2019)